Testing gut bacteria in gynecologic cancer patients on immunotherapy
Part of Cancer clinical trials.
This study looks at how gut bacteria may relate to how well immunotherapy works in people with advanced or returning gynecologic cancer. You may be asked to give stool samples several times so researchers can measure changes in your gut microbiome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult woman older than 18 years
- Have advanced or recurrent gynecologic cancer and be cared for through the AHMG Advent Health Orlando Gynecologic Oncology Group
- Have an immunotherapy treatment plan already ordered by your care team
- Be able and willing to collect stool (fecal) samples at three different time points
- Be able to read and understand the informed consent form (or have support to do so)
- Avoid certain medicines before and during the study, especially antibiotics, laxatives, proton pump inhibitors, and metformin, and not be on another investigational (study) drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the bacteria in your gut might affect how well immunotherapy works for certain cancers. It is for people with advanced lung cancer, melanoma, or certain gynecologic cancers who are about to start immunotherapy, and it may help doctors understand why some people respond better than others.
This trial studies whether changes in gut bacteria can help predict how well immunotherapy works for solid cancers. It also tests whether stool (fecal microbiota) from certain immunotherapy-responding people can improve outcomes for others who are not responding well.
This study looks at the bacteria in your mouth, gut, and tumors to see if they affect how well first-line immunotherapy works. It is for people with advanced stomach, colorectal, breast, cervical, or head-and-neck cancer.
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
This study looks at how immune checkpoint inhibitor (ICI) therapy—a type of cancer treatment that boosts your immune system—affects ovarian function and fertility in female cancer patients. It also explores the role of gut bacteria in these effects. The study aims to understand changes that may help guide fertility preservation decisions.
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
Hear when a new Gynecologic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.